Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Jaypirca (pirtobrutinib)
i
Other names:
LOXO-305, REDX08608, LOXO 305, RXC 005, RXC005, RXC-005, LY3527727
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(13)
News
Trials
Company:
Eli Lilly, Innovent Biologics
Drug class:
BTK inhibitor
Related drugs:
‹
ibrutinib (186)
zanubrutinib (55)
acalabrutinib (41)
orelabrutinib (23)
TG-1701 (7)
CG-806 (6)
M7583 (4)
DZD9008 (3)
JNJ-4681 (2)
abivertinib (1)
SRX3262 (1)
SNS-062 (1)
AS-1763 (0)
DTRM-555 (0)
DTRMWXHS-12 (0)
DZD8586 (0)
GB5121 (0)
HMPL-760 (0)
HZ-A-018 (0)
KIN-8194 (0)
LP-168 (0)
NRX0492 (0)
TT-01488 (0)
tirabrutinib (0)
GDC-0853 (0)
MK-1026 (0)
HM71224 (0)
CC-292 (0)
ibrutinib (186)
zanubrutinib (55)
acalabrutinib (41)
orelabrutinib (23)
TG-1701 (7)
CG-806 (6)
M7583 (4)
DZD9008 (3)
JNJ-4681 (2)
abivertinib (1)
SRX3262 (1)
SNS-062 (1)
AS-1763 (0)
DTRM-555 (0)
DTRMWXHS-12 (0)
DZD8586 (0)
GB5121 (0)
HMPL-760 (0)
HZ-A-018 (0)
KIN-8194 (0)
LP-168 (0)
NRX0492 (0)
TT-01488 (0)
tirabrutinib (0)
GDC-0853 (0)
MK-1026 (0)
HM71224 (0)
CC-292 (0)
›
Associations
(13)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
pirtobrutinib
Sensitive: A1 - Approval
pirtobrutinib
Sensitive
:
A1
pirtobrutinib
Sensitive: A1 - Approval
pirtobrutinib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
pirtobrutinib
Sensitive: A1 - Approval
pirtobrutinib
Sensitive
:
A1
pirtobrutinib
Sensitive: A1 - Approval
pirtobrutinib
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
pirtobrutinib
Sensitive: A1 - Approval
pirtobrutinib
Sensitive
:
A1
pirtobrutinib
Sensitive: A1 - Approval
pirtobrutinib
Sensitive
:
A1
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
pirtobrutinib
Sensitive: A2 - Guideline
pirtobrutinib
Sensitive
:
A2
pirtobrutinib
Sensitive: A2 - Guideline
pirtobrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
pirtobrutinib
Sensitive: A2 - Guideline
pirtobrutinib
Sensitive
:
A2
pirtobrutinib
Sensitive: A2 - Guideline
pirtobrutinib
Sensitive
:
A2
TP53 mutation
Chronic Lymphocytic Leukemia
TP53 mutation
Chronic Lymphocytic Leukemia
pirtobrutinib
Sensitive: A2 - Guideline
pirtobrutinib
Sensitive
:
A2
pirtobrutinib
Sensitive: A2 - Guideline
pirtobrutinib
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
pirtobrutinib
Sensitive: A2 - Guideline
pirtobrutinib
Sensitive
:
A2
pirtobrutinib
Sensitive: A2 - Guideline
pirtobrutinib
Sensitive
:
A2
TP53 mutation + Chr del(17p)
Small Lymphocytic Lymphoma
TP53 mutation + Chr del(17p)
Small Lymphocytic Lymphoma
pirtobrutinib
Sensitive: C3 – Early Trials
pirtobrutinib
Sensitive
:
C3
pirtobrutinib
Sensitive: C3 – Early Trials
pirtobrutinib
Sensitive
:
C3
TP53 mutation + Chr del(17p)
Chronic Lymphocytic Leukemia
TP53 mutation + Chr del(17p)
Chronic Lymphocytic Leukemia
pirtobrutinib
Sensitive: C3 – Early Trials
pirtobrutinib
Sensitive
:
C3
pirtobrutinib
Sensitive: C3 – Early Trials
pirtobrutinib
Sensitive
:
C3
BTK C481S
Chronic Lymphocytic Leukemia
BTK C481S
Chronic Lymphocytic Leukemia
pirtobrutinib
Sensitive: C3 – Early Trials
pirtobrutinib
Sensitive
:
C3
pirtobrutinib
Sensitive: C3 – Early Trials
pirtobrutinib
Sensitive
:
C3
BTK C481
Chronic Lymphocytic Leukemia
BTK C481
Chronic Lymphocytic Leukemia
pirtobrutinib
Sensitive: C3 – Early Trials
pirtobrutinib
Sensitive
:
C3
pirtobrutinib
Sensitive: C3 – Early Trials
pirtobrutinib
Sensitive
:
C3
BTK C481
Small Lymphocytic Lymphoma
BTK C481
Small Lymphocytic Lymphoma
pirtobrutinib
Sensitive: C3 – Early Trials
pirtobrutinib
Sensitive
:
C3
pirtobrutinib
Sensitive: C3 – Early Trials
pirtobrutinib
Sensitive
:
C3
TP53 mutation
Mantle Cell Lymphoma
TP53 mutation
Mantle Cell Lymphoma
pirtobrutinib
Sensitive: C3 – Early Trials
pirtobrutinib
Sensitive
:
C3
pirtobrutinib
Sensitive: C3 – Early Trials
pirtobrutinib
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login